[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"retinal-ischemia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:retinal-ischemia":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,58,95],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":47,"lastUpdatePostDateStruct":48,"startDateStruct":51,"completionDateStruct":52,"leadSponsor":54,"locationsCount":57},"100625264","ambulatory-stroke-unit-treatment-for-elderly-patients-100625264",false,"NCT07420374","Ambulatory Stroke Unit Treatment for Elderly Patients","Ambulatory Stroke Unit Treatment for Elderly Patients: A Prospective, Randomized, Controlled, Exploratory Non-Inferiority Trial (ARTIFICE)","ARTIFICE","Inclusion Criteria:\n\n* Age ≥ 60 years\n* Diagnosis of acute ischemic stroke (ICD-10 I63.), transient ischemic attack (G45.), or retinal ischemia (H34.\\*)\n* Symptom onset ≤ 7 days before enrollment\n* No or non-disabling newly occurring neurological deficit allowing safe ambulatory management\n* Written informed consent provided by the participant or, if lacking decision-making capacity, by a legally authorized representative\n\nExclusion Criteria:\n\n* Requirement for urgent surgical or interventional secondary prevention (e.g., carotid revascularization)\n* Fluctuating stroke symptoms within the previous 48 hours\n* Acute febrile infection or isolation-requiring infectious disease\n* Clinically relevant dysphagia with high aspiration risk\n* Critical medical or nursing findings requiring mandatory multi-day inpatient treatment\n* Palliative care situation with limitation of acute diagnostic or therapeutic measures\n* Previous participation in the ambulatory stroke unit care model\n* No statutory health insurance coverage in Germany\n* Insufficient German language proficiency to understand study procedures and assessments","ALL","60 Years",{"count":20,"type":21},400,"ESTIMATED","INTERVENTIONAL",[24],"NA","ARTIFICE is a prospective, multicenter, randomized, controlled, exploratory non-inferiority trial evaluating whether an ambulatory stroke unit model (aSU) is non-inferior to conventional inpatient stroke unit care (SU) in patients aged 60 years or older with acute ischemic stroke, transient ischemic attack (TIA), or retinal ischemia and non-disabling neurological deficits.\n\nEligible patients are randomized 1:1 to same-day comprehensive ambulatory multiprofessional stroke evaluation (aSU) or guideline-based inpatient stroke unit treatment (SU). The primary endpoint is favorable functional outcome at 90 days, defined as modified Rankin Scale (mRS) 0-2 or return to pre-stroke mRS. Endpoint assessment at 90 days is performed by blinded assessors (PROBE design).\n\nSecondary outcomes include early neurological deterioration, recurrent stroke, delirium, mortality, health-related quality of life, healthcare utilization, and cost-effectiveness. A mixed-methods process evaluation examines feasibility, acceptability, and implementation aspects of the ambulatory care model.",[27,28,29],"Ischemic Stroke","Transient Ischemic Attack (TIA)","Retinal Ischemia",[31,32,33,34,35,36,37,38,39,40,41,42,43,44,45],"Ambulatory Stroke Unit","Stroke Unit Care","Minor Stroke","Transient Ischemic Attack","Geriatric Stroke","Non-Inferiority Trial","Health Services Research","Care Delivery Model","Integrated Stroke Care","Post-Stroke Outcome","Modified Rankin Scale","Quality of Life","Cost-Effectiveness","Stroke Recurrence","Delirium","RECRUITING","2026-03-25",{"date":49,"type":50},"2026-03-31","ACTUAL",{"date":47,"type":50},{"date":53,"type":21},"2028-12",{"name":55,"class":56},"University Hospital Heidelberg","OTHER",1,{"id":59,"slug":60,"hasResults":11,"nctId":61,"briefTitle":62,"officialTitle":62,"acronym":63,"eligibilityCriteria":64,"healthyVolunteers":11,"sex":17,"minAge":65,"maxAge":4,"enrollmentInfo":66,"targetDuration":4,"studyType":68,"phases":4,"briefSummary":69,"conditions":70,"keywords":79,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":57},"100554564","visual-involvement-in-giant-cell-arteritis-100554564","NCT06500728","Visual Involvement in Giant Cell Arteritis","Visu-GCA","Inclusion Criteria:\n\n* For GCA group:\n\n  * Patients older than 18 years with clinically suspected or confirmed gigantocellular arteritis.\n  * Newly found visual involvement with suspected or confirmed correlation with vasculitis.\n  * Ability to express valid consent to study enrolment.\n* For control group:\n\n  * Patients older than 18 years with the ability to express valid consent to study enrolment.\n  * Newly diagnosed acute visual impairment with GCA phenotypes (e.g. AION, CRAO) but without any correlation with vasculitis aetiology.\n\nExclusion Criteria:\n\n* Pre-existing ophthalmological pathologies that may modify best visual acuity and\u002For alter ophthalmological semeiotics.\n* Concomitant active viral, bacterial, fungal and parasitic infections, including active or latent tuberculosis treated for less than 4 weeks and HIV, hepatitis C virus (HCV)\n\n  \u002Fhepatitis B virus (HBV) infections, involving the eyes and orbital cavities.\n* Concomitant systemic inflammations not attributable to GCA (inflammatory diseases in treatment-free remission are not excluded).\n* Any other condition judged by the investigators to be a contraindication of eligibility","18 Years",{"count":67,"type":21},762,"OBSERVATIONAL","This observational study aims to enhance the description of the different ways Giant Cell Arteritis (GCA) affects vision. The latest technology and knowledge are used to improve how we diagnose and predict patient outcomes. GCA is the most frequent vasculitis, an inflammation of vessels, in older adults. It involves large and medium-sized arteries and causes ischemic alterations such as stroke and blindness, through damage of extracranial arteries.\n\nThe primary objective is to compare the frequency of the various ocular findings between the main alterations of arteritic and non-arteritic aetiology, such as Arteritic Anterior Ischemic Optic Neuropathy (A-AION) Vs. Non-Arteritic Anterior Ischemic Optic Neuropathy (NA-AION) or Central Retinal Artery Occlusion (CRAO) from GCA Vs. from other causes, through a comprehensive clinical and instrumental evaluation.",[71,72,73,74,75,76,29,77,78],"Giant Cell Arteritis","Visual Impairment","Central Retinal Artery Occlusion","Anterior Ischemic Optic Neuropathy","Paracentral Acute Middle Maculopathy","Posterior Ischemic Optic Neuropathy","Blindness","Visual Disorder",[71,80,81,82,83,84,85],"Visual impairment","Optical Coherence Tomography (OCT)","High resolution Optical Coherence Tomography (HR-OCT)","Angio-Optical Coherence Tomography (OCT-A)","Fluorescein angiography","Indocyanine green angiography","2024-07-08",{"date":88,"type":50},"2024-07-15",{"date":90,"type":50},"2024-06-27",{"date":92,"type":21},"2030-06",{"name":94,"class":56},"ASST Fatebenefratelli Sacco",{"id":96,"slug":97,"hasResults":11,"nctId":98,"briefTitle":99,"officialTitle":99,"acronym":100,"eligibilityCriteria":101,"healthyVolunteers":11,"sex":17,"minAge":102,"maxAge":4,"enrollmentInfo":103,"targetDuration":4,"studyType":68,"phases":4,"briefSummary":105,"conditions":106,"keywords":4,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":57},"100549261","fundus-optical-coherence-tomography-angiography-evaluation-for-small-vessel-health-in-cerebral-small-vessel-disease-100549261","NCT06431711","Fundus Optical coheRence Tomography Angiography Evaluation for Small-vessel Health in Cerebral Small Vessel Disease","FRESH-CSVD","Inclusion Criteria:\n\n1. Older than 35 years old;\n2. Patients who underwent Multimodal MRI with any CSVD imaging marker;\n3. Subjects who have signed informed consent.\n\nExclusion Criteria:\n\n1. Patient who was unable to cooperate with examinations;\n2. There are known diseases that may cause or worsen CSVD (brain injury, Down syndrome, Alzheimer's disease, Parkinson's disease, etc.);\n3. There are known eye diseases or severe underlying fundus lesions that may impact fundus assessment;\n4. Suffering from serious systemic diseases, such as heart, liver, kidney diseases or major mental illnesses;\n5. Contraindications for imaging examinations\n\nExit Criteria:\n\n1. Not meet the inclusion criteria.\n2. For any poor adherence, not comply with the requirements of the follow-up, or safety reasons determined by investigator.\n3. Any adverse or serious adverse events during the study period judged by investigator","35 Years",{"count":104,"type":21},2400,"Cerebral small-vessel disease (CSVD) is a significant contributor to stroke and dementia, primarily impacting individuals over the age of 60. Its prevalence exceeds 70% in the elderly population, imposing a substantial burden on brain health and the economy. Optical coherence tomography angiography (OCTA) is a new type of optical diagnostic imaging technology for non-invasive detection, which can perform multi-dimensional quantitative assessment of fundus retinopathy. Current studies have shown that fundus OCTA-derived parameters may have potential in characterizing imaging changes in CSVD. However, the correlation between retinal\u002Fchoroidal parameters on OCTA and the CSVD imaging markers remains uncertain. FRESH-CSVD is a prospective, observational study that will use fundus OCTA-derived parameters to screen patients with CSVD, explore the relationship between relevant parameters based on OCTA measurements and CSVD, and evaluate the feasibility and clinical value of identification of CSVD through fundus OCTA.",[107,29,108],"Cerebral Small Vessel Diseases","Choroid; Injury","2024-05-27",{"date":111,"type":50},"2024-05-29",{"date":113,"type":50},"2024-04-01",{"date":115,"type":21},"2034-03-31",{"name":117,"class":56},"Zhejiang Provincial People's Hospital"]